NANOTRIGGER

Triggerable nanomaterials to modulate cell activity

Coordinatore	CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Portugal [PT]
Totale costo	1˙699˙320 €
EC contributo	1˙699˙320 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-StG_20111012
Funding Scheme	ERC-SG
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-11-01   -   2017-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO  Organization address address: UNIVERSIDADE DE COIMBRA . city: COIMBRA postcode: 3004 517 contact info Titolo: Dr. Nome: Lino Cognome: Da Silva Ferreira Email: send email Telefono: 351231000000 Fax: 351231000000	PT (COIMBRA)	hostInstitution	1˙699˙320.00
2	CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO  Organization address address: UNIVERSIDADE DE COIMBRA . city: COIMBRA postcode: 3004 517 contact info Titolo: Dr. Nome: Silvia Cognome: Sousa Email: send email Telefono: 351240000000 Fax: 351240000000	PT (COIMBRA)	hostInstitution	1˙699˙320.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The advent of molecular reprogramming and the associated opportunities for personalised and therapeutic medicine requires the development of novel systems for on-demand delivery of reprogramming factors into cells in order to modulate their activity/identity. Such triggerable systems should allow precise control of the timing, duration, magnitude and spatial release of the reprogramming factors. Furthermore, the system should allow this control even in vivo, using non-invasive means. The present project aims at developing triggerable systems able to release efficiently reprogramming factors on demand. The potential of this technology will be tested in two settings: (i) in the reprogramming of somatic cells in vitro, and (ii) in the improvement of hematopoietic stem cell engraftment in vivo, at the bone marrow. The proposed research involves a team formed by engineers, chemists, biologists and is highly multidisciplinary in nature encompassing elements of engineering, chemistry, system biology, stem cell technology and nanomedicine.'